Two piperazine-containing 3,4-dihyroquinazolines (BK10007S/8S) have been synthesized, based on our previous work on the synthesis and antitumoral activity of 3,4-dihyroquinazolines. After evaluating them for T-type calcium channel blocking effect and in vitro anti-cancer effect, they were profiled for acute and repeat dose toxicity (40 mg/kg, 2 weeks) to BALB/c mice. BK10007S/8S were further in vivo evaluated against human pancreatic MIA PaCa-2 carcinoma in $BALB/c^nu/nu}$ nude mice, which exhibited 54 and 61% tumor growth inhibition through 57-day oral administration of 2 mg/kg of body weight, respectively.
基于我们对3,4-二氢
喹唑啉合成及其抗癌活性的先前工作,合成了两种含有
哌嗪的3,4-二氢
喹唑啉(BK10007S/8S)。经过对其T型
钙通道阻断效应和体外抗癌效应的评估后,对其在BALB/c小鼠中进行了急性和重复剂量毒性(40 mg/kg,2周)的轮廓分析。进一步在体内评估了BK10007S/8S对人类胰腺癌MIA PaCa-2在
$BALB/c^nu/nu}$裸鼠中的作用,通过57天口服给药2 mg/kg体重,分别显示出54%和61%的肿瘤生长抑制。